Business Context and Reporting Period
This Form 6-K filing by GlaxoSmithKline plc (GSK) covers the period ending November 2012. The report details a specific share repurchase transaction executed on November 13, 2012, in accordance with shareholder authority granted at the Annual General Meeting on May 3, 2012.
Key Financial Metrics
The filing does not provide comprehensive financial statements such as revenue, profit, cash flow, margins, debt, or liquidity metrics. The only financial data disclosed relates to the share buyback transaction:
- Shares Purchased: 600,000 Ordinary Shares of 25 pence each.
- Price Range: Highest price paid was 1,357.0 pence per share; lowest price paid was 1,337.5 pence per share.
- Treasury Holdings: Post-transaction, the Company holds 527,640,427 shares in Treasury (9.69% of total issued share capital).
- Total Voting Rights: Including unsettled purchases, Treasury holdings represent 10.77% of current total voting rights.
- Shares in Issue: 4,917,856,972 shares (excluding Treasury shares).
Material Changes
The filing reports a reduction in the number of shares outstanding due to the repurchase of 600,000 shares. Consequently, the percentage of shares held in Treasury increased to 9.69% of total issued share capital. No other material changes to operations or financial position are disclosed in this specific document.
Guidance, Outlook, and Risks
The filing contains no management commentary, forward-looking guidance, outlook, or discussion of risks and contingencies. It is a compliance announcement confirming adherence to the Financial Services Authority's Disclosure and Transparency Rules regarding share buybacks.
Key Facts for Investor Verification
- Verify the total cost of the 600,000 share repurchase based on the disclosed price range (1,337.5 to 1,357.0 pence).
- Confirm the updated total issued share capital and the specific impact on earnings per share (EPS) calculations, as the denominator for voting rights is now 4,917,856,972 shares.
- Check subsequent filings for the settlement status of the shares mentioned as "purchased but not yet settled" which contributed to the 10.77% voting rights figure.
- Note that this filing does not contain quarterly or annual financial performance data; investors must refer to Form 20-F or other periodic reports for revenue and profit metrics.